Replies to post #150870 on Biotech Values

[Summer2762]

That difference surely outweighs any small time advantage.

You are right. However, my intent was not to discuss this in the context of the AFFIRM trial but to see how it applies to the SYNERGY trial as OGX-011 probably has a different mechanism than enzalutamide and abiraterone acetate .